SCHEMBL6660965

SCHEMBL6660965

COc1ccc(C2=NN(Cc3cccc(NC(=O)c4ccc[nH]4)c3)C(=O)SC2)cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 8/20 0.63
PDE4A P27815 4/20 0.63
PDE4C Q08493 4/20 0.63
PDE4D Q08499 4/20 0.63
MET P08581 3/20 0.63
PDE3B Q13370 2/20 0.63
PDE3A Q14432 2/20 0.63
ITGB3 P05106 1/20 0.43
ITGAV P06756 1/20 0.43
ACKR3 P25106 2/20 0.41
PARP1 P09874 1/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GAA P10253 1/20 0.40
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6655909 0.92 PDE4B (0.53) PDE4BPDE4APDE4CPDE4DMET
SCHEMBL6655377 0.88 PDE4B (0.61) PDE4BPDE4APDE4CPDE4DMET
SCHEMBL6657302 0.87 PDE4B (0.63) PDE4BPDE4APDE4CPDE4DMET
SCHEMBL6686835 0.87 PDE4B (0.65) PDE4BPDE4APDE4CPDE4DMET
SCHEMBL7800598 0.86 PDE4B (0.70) PDE4BPDE4APDE4CPDE4DMET
SCHEMBL7802139 0.86 PDE4B (0.70) PDE4BPDE4APDE4CPDE4DMET
SCHEMBL7793051 0.86 PDE4B (0.75) PDE4BPDE4APDE4CPDE4DMET
SCHEMBL6656975 0.86 PDE4B (0.48) PDE4BPDE4APDE4CPDE4DMET
SCHEMBL6659738 0.86 PDE4B (0.66) PDE4BPDE4APDE4CPDE4DMET
SCHEMBL6843893 0.85 PDE4B (0.47) PDE4BPDE4APDE4CPDE4DMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B PDE4B 4/4885PDE4A 1/4885PDE4C 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.